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A population pharmacokinetic analysis was conducted on nelfinavir in patients infected with human im-
munodeficiency virus (HIV) who were enrolled in a phase III clinical trial. The data consisted of 509 plasma
concentrations from 174 patients who received nelfinavir at a dose of 500 or 750 mg three times a day. The
analysis was performed using nonlinear mixed-effect modeling as implemented in NONMEM (version 4.0;
double precision). A one-compartment model with first-order absorption best described the data. The timing
and small number of early postdose blood levels did not allow accurate estimation of volume of distribution
(V/F) and the absorption rate constant (ka). As a result, two models were used to analyze the data: model 1, in
which oral clearance (CL/F), V/F, and ka were estimated, and model 2, in which V/F and ka were fixed to known
values and only CL/F was estimated. Estimates of CL/F ranged from 41.9 to 45.1 liters/h, values in close
agreement with previous studies. Neither body weight, age, sex, race, dose level, baseline viral load, metabolite-
to-parent drug plasma concentration ratio, history of liver disease, nor elevated results of liver function tests
appeared to be significant covariates for clearance. The only significant covariate-parameter relationship was
concomitant use of fluconazole on CL/F, which was associated with a modest reduction in interindividual
variability of CL/F. Patients who received concomitant therapy with fluconazole had a statistically significant
reduction in nelfinavir CL/F of 26 to 30%. Since serious dose-limiting toxicity and concentration-related
toxicities are not apparent for nelfinavir, this effect of fluconazole is unlikely to be of clinical significance.
Nelfinavir mesylate (Viracept) is a protease inhibitor ap-
proved for use in the treatment of human immunodeficiency
virus (HIV) infection by the Food and Drug Administration
(FDA) in March 1997. The currently recommended adult dose
is 750 mg three times a day (TID) taken with or after food
(Agouron prescribing information, Agouron Pharmaceuticals,
La Jolla, Calif., 1998), and an alternative 1,250-mg twice-daily
dosage regimen has been recently approved by the FDA. Phar-
macokinetic studies of nelfinavir have previously been con-
ducted in phase I and phase II of clinical drug development (9,
11). When nelfinavir was administered at a dose of 500 or 750
mg TID, the peak plasma concentration (Cmax) at steady state
was in the range of 3 to 4 mg/ml and the time to peak concen-
tration (Tmax) was in the range of 2.5 to 3 h (9). The half-life
of nelfinavir has been reported in these studies as 3 to 5 h (9,
11).
Nelfinavir, like the other currently available protease inhib-
itors, ritonavir, indinavir, saquinavir, and amprenavir, is me-
tabolized by the cytochrome P450 system (6, 7, 9, 10, 13; C. A.
Lee, B.-H. Liang, E. Y. Wu, H. M. Grettenberger, T. M.
Sandoval, K. E. Zhang, and B. V. Shetty, Abstr. 4th Natl. Conf.
Hum. Retroviruses Related Infect., 1997; J. L. Lillibridge,
C. A. Lee, Y. K. Pithavala, T. M. Sandoval, E. Y. Wu, K. E.
Zhang, E. L. Mazabel, M. Zhang, and B. M. Kerr, Abstr. 5th
Int. ISSX Meet., abstr. 109, 1998; E. Y. Wu, T. M. Sandoval,
K. E. Zhang, H. M. Grettenberger, B. R. Hee, C. A. Lee, S.
Webber, and B. V. Shetty, Abstr. 5th Int. ISSX Meet., abstr.
110, 1998; M. H. Zhang, Y. K. Pithavala, C. A. Lee, J. H.
Lillibridge, E. Y. Wu, T. M. Sandoval, R. G. Daniels, and B. M.
Kerr, Abstr. 12th Int. Symp. Microsomes Drug Oxidations,
abstr. 264, 1998). In vitro studies have shown that CYP3A4 and
CYP2C19 are the predominant isoenzymes involved in the
metabolism of nelfinavir (Lillibridge et al., 5th Int. ISSX Meet.;
Wu et al., 5th Int. ISSX Meet.; Zhang et al., 12th Int. Symp.
Microsomes Drug Oxidations). Other isoenzymes CYP2D6
and CYP2C9 are involved to a lesser extent (13; B. Kerr, G.
Yuen, R. Daniels, B. Quart, and R. Anderson, Abstr. Natl.
Conf. Hum. Retroviruses Related Infect., 1997; Lee et al., 4th
Natl. Conf. Hum. Retroviruses Related Infect., Wu et al., 5th
Int. ISSX Meet.). Nelfinavir has one major metabolite,
M8 (also referred to as nelfinavir hydroxy-t-butylamide or
AG1402), in human plasma. This metabolite has been shown
to have an antiviral potency in vitro similar to that of nelfinavir
(10; Lillibridge et al., 5th Int. ISSX Meet.; Zhang et al. 12th
Int. Symp. Microsomes Drug Oxidations). The generation of
this metabolite appears to be exclusively catalyzed by CYP2C19
(5; Lillibridge et al., 5th Int. ISSX Meet.; Wu et al., 5th Int. ISSX
Meet.). Studies have demonstrated that CYP2C19 exhibits ge-
netic polymorphism (8); 2 to 6% of Caucasians and 18 to 22%
of Asians are poor metabolizers of CYP2C19.
The development of resistance to protease inhibitors, like
that to other antiretroviral therapies, is of major concern. It
has been observed that resistance is more likely to develop
when plasma concentrations of protease inhibitors are sub-
* Corresponding author. Mailing address: Department of Applied
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therapeutic (2). Therefore it is important to characterize the
pharmacokinetics of nelfinavir in a representative patient pop-
ulation and to try and identify variables that may lead to lower
plasma concentrations, which in turn may increase the risk of
therapeutic failure. In particular, due to the extensive metab-
olism of nelfinavir by cytochrome P450 enzymes, there is the
potential for drug interactions that affect nelfinavir concentra-
tions to occur. This is especially of concern in patients with
HIV disease, as these patients often take concomitant medi-
cations which are known to induce or inhibit cytochrome P450.
Thus, the objectives of this study were to determine the
population pharmacokinetic parameters of nelfinavir and their
variability in an HIV-infected patient population, to determine
the influence of patient characteristics on the pharmacokinetic
parameters of nelfinavir, and to investigate potential pharma-
cokinetic drug interactions.
MATERIALS AND METHODS
Concentration-time data were obtained from patients enrolled in a phase III
clinical study, which was primarily designed to evaluate the safety and efficacy of
nelfinavir in HIV-infected patients. A secondary objective of the study was to
determine the population pharmacokinetic parameters of nelfinavir. Safety and
efficacy results have been reported elsewhere (N. Clendennin, B. Quart, R.
Anderson, M. Knowles, and Y. Chang, Abstr. 5th Conf. Retroviruses Opportu-
nistic Infect., abstr. 372, 1998; M. Saag, M. Knowles, Y. Chang, S. Chapman, and
N. J. Clendennin, Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother.,
1997). This paper presents the results of the population pharmacokinetic anal-
ysis.
Study population. The study population included patients aged 13 years or
older with HIV infection who had received either no prior antiretroviral therapy
or less than 1 month of treatment with zidovudine (AZT). Patients were required
to have a baseline plasma HIV RNA titer of $15,000 copies/ml. Participants in
the trial were randomized to receive nelfinavir at 500 or 750 mg TID or placebo.
All patients received concomitant therapy with AZT (200 mg TID) and lamivu-
dine (150 mg twice a day). Randomization was stratified according to the pa-
tient’s baseline CD4 count (less than 100 cells per ml, 100 to 300 cells per ml, or
greater than 300 cells per ml) to ensure that the treatment groups were balanced.
Concentration-time data were obtained from 174 participants who received one
of the nelfinavir dosage regimens. These patients were enrolled at 27 investiga-
tive sites.
Exclusion criteria at baseline examination included prior antiretroviral ther-
apy, therapy with immune modulators or vaccines within 1 month of baseline,
patients of procreative potential who were not practicing double-barrier contra-
ception, elevated liver function tests (LFTs) or hemoglobin or bilirubin levels,
decreased neutrophil or platelet counts, renal insufficiency, acute pancreatitis or
hepatitis, significant fever or diarrhea, malabsorption syndrome, severe intermit-
tent medical conditions including opportunistic infections, active substance
abuse, neoplastic disease requiring radiation or cytotoxic therapy, and females
taking oral contraceptives. The appropriate institutional review boards approved
the study, and written informed consent was obtained from all participants.
Plasma samples. The pharmacokinetic study was of an observational, popu-
lation design. Patients had blood samples drawn for analysis of nelfinavir con-
centrations during clinical follow-up visits. In general, each individual provided
two blood samples per visit: a predose trough sample and a postdose sample
collected approximately 2 h after the dose taken during the visit. Doses of
nelfinavir were given with food at these visits. The majority of individuals were
sampled at weeks 2 and 8 of the study; hence all concentrations were considered
to be at steady state. Ultimately, 509 samples from 174 patients were used in the
pharmacokinetic analysis. This was an average of approximately three samples
per patient (range of one to six).
Plasma sample analysis. Plasma concentrations of nelfinavir and M8 were
measured by a validated method using high-performance liquid chromatography
and UV detection. The published version of this method (16) was modified
slightly (the mobile phase consisted of 32.5% acetonitrile plus 7.5% methanol
instead of 42% acetonitrile and the flow rate was adjusted to 1.5 ml/min) to
accommodate the analysis of M8. The lower and upper limits of quantification
were 0.05 and 10.0 mg/liter, respectively, for each analyte. For this study, assay
correlation coefficients (16 analytical runs) exceeded 0.994 for nelfinavir and
0.997 for M8. Based on quality control samples, interday accuracy for the two
analytes ranged from 97 to 101% of nominal concentration and interday preci-
sion expressed as a percent coefficient of variation was less than 10%.
Data preparation and pharmacokinetic analysis. Clinical, pharmacokinetic,
and demographic data relevant to the population pharmacokinetic analysis were
extracted from the raw data sets and merged and formatted using SAS (version
6.09) on an IBM ES-9000 computer. The pharmacokinetic analysis was per-
formed using NONMEM (version 4.0, double precision) (S. L. Beal and L. B.
Sheiner [ed.], NONMEM user’s guide, NONMEM Project Group, University of
California at San Francisco, San Francisco) on an IBM ES-9000 computer.
Initially, the analysis was performed using the first-order (FO) method for pa-
rameter estimation, and the results were subsequently confirmed using the first-
order conditional estimation (FOCE) method.
Pharmacokinetic model. Several pharmacokinetic models were used to fit the
data. A one-compartment model and a two-compartment open model with
first-order absorption and first-order elimination were tested. In addition, a
zero-order input to a one-compartment model was tested using an input period
of 3 h (the average value of Tmax for nelfinavir [range of 2 to 4 h], as reported
previously [Agouron prescribing information]). The first-order input to the one-
compartment model was parameterized as the first order absorption rate con-
stant (ka), oral clearance (CL/F), and volume of distribution (V/F), and the
zero-order input to the one-compartment model was parameterized as CL/F and
V/F. The two-compartment model was parameterized as ka, CL/F, volume of the
central compartment (Vc/F), volume of distribution at steady state (Vss/F), and
intercompartmental clearance (Q). The model that best fit the data was selected
for further analyses.
Statistical model. An exponential-error model and a proportional-error model
were evaluated to describe interindividual variability. The models were uj 5
u9exp(huj) (exponential-error model) and uj 5 u9[1 1 (hui)] (proportional-error
model) where uj is the estimate for a pharmacokinetic parameter in the jth
individual as predicted by the regression model, u9 is the population mean of the
pharmacokinetic parameter, and huj represents the random variable with zero
mean and variance v2 that distinguishes the jth individual pharmacokinetic
parameter from the population mean value predicted by the regression model.
Terms for interindividual variability were included for CL/F, V/F, and ka.
Residual variability (including intraindividual variability) was modeled using
either a proportional-error model or a combined proportional- and additive-
error model. The equations used were Cij 5 C9ij(1 1 e 1ij) and Cij 5 [C9ij(1 1
e 1ij)] 1 e 2ij where Cij is the observed serum concentration for the jth individual
at time i, C9ij is the model predicted serum concentration for the jth individual at
time i, and e 1ij and e 2ij are the components of the proportional and additive
errors (with zero mean and variance s2), respectively.
Data analysis strategy. The pharmacokinetic and statistical models were eval-
uated to determine the basic model that best fit the data. A statistically significant
decrease (P 5 0.05) in the minimum value of the objective function (as measured
by the log likelihood difference) found when comparing reduced to full models,
visual inspection of weighted residual plots, and an evaluation of the precision of
pharmacokinetic parameter and variability estimates were used as criteria to
determine the best basic model.
After the basic model was constructed, a model-building process was em-
ployed to examine the influence of patient covariates on the estimates of the
pharmacokinetic parameters. The effects of the following patient covariates were
evaluated: age, weight, sex, ethnic origin, dose, baseline HIV disease status,
history of liver disease, elevated LFTs, metabolite-to-parent drug (M8-to-nelfi-
navir) plasma concentration ratio, and use of concomitant medications.
Age and weight were examined as continuous variables. Sex, dose, ethnic
origin, and history of liver disease were examined as categorical variables. The
effect of an increase in LFTs was examined as a dichotomous variable, a change
of either grade two and higher or less than grade two. The HIV disease status of
the patient at entry into the study was characterized by baseline CD4 count and
baseline viral load. The CD4 count was categorized into three groups as follows:
less than 100 cells per ml, 100 to 300 cells per ml, and greater than 300 cells per
ml. Viral load measurements were also split into three categories: greater than
100,000 copies/ml, 50,000 to 100,000 copies/ml, and less than 50,000 copies/ml.
The baseline level of circulating HIV RNA in plasma was estimated using an
experimental branched-DNA signal amplification assay (second-generation Chi-
ron branched-DNA assay). The M8-to-nelfinavir plasma ratio (a reflection of
CYP2C19 enzyme activity) was investigated as a potential covariate both as a
continuous variable and as a categorical variable. This was determined, where
possible, from the M8-to-nelfinavir concentration ratio in the 2-h postdose
plasma samples. Ratio values were empirically categorized into three groups: a
ratio less than 0.1 was considered low, a ratio between 0.1 and 0.3 was considered
intermediate, and a ratio greater than 0.3 was considered high (Lillibridge et al.,
5th Int. ISSX Meet.). It should be noted that metabolite data were only available
for 110 of the 174 patients in this study. As CYP3A4 and CYP2C19 play impor-
tant roles in the elimination of nelfinavir (Kerr et al., Natl. Conf. Hum. Retro-
viruses Related Infect.; Lee et al., 4th Natl. Conf. Hum. Retroviruses Related
Infect.; Zhang et al. 12th Int. Symp. Microsomes Drug Oxidations), concomitant
medications known to inhibit or induce these isoenzymes were examined as
potential covariates. The effects of macrolide antibiotics and quinolone antibi-
otics were examined as a class rather than on an individual basis to increase the
number of patients in each covariate group. In this study, patients taking an azole
antifungal consisted mainly of patients taking fluconazole; thus, the effect of
fluconazole alone was investigated as was the effect of concomitant therapy with
rifabutin.
A decrease in the minimum value of the objective function of 3.8 or greater
following introduction of a single covariate into the model was considered sta-
tistically significant (P 5 0.05) using the x2 distribution if the 95% confidence
intervals (CI) for the estimate did not include the null value. If the change in the
objective function was 3.8 or greater but the 95% CI for the estimate included
the null value, the effect of the variable was considered to be of borderline
VOL. 44, 2000 PHARMACOKINETIC ANALYSIS OF NELFINAVIR MESYLATE 1833
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significance and that covariate was not included in the full model. All significant
variables were included in the full model. It was assumed that no significant
interactions between covariate factors existed. If there was an interaction present
for an effect that was not significant alone at the P 5 0.05 level, then this effect
would be minor and would not be likely to be of clinical significance. Thus,
covariate effects were introduced individually and no covariate-covariate inter-
actions were modeled.
A backward elimination process was then employed to eliminate covariates
from the full model in order to develop the final model. An increase in the
objective function of 3.8 or greater (P 5 0.05) on removal of a covariate from the
full model signified that the variable was important, and that covariate was
retained in the final model.
Minimal pharmacokinetic model. It was difficult to obtain accurate estimates
of V/F and ka during this analysis. To assess the impact of possible misestimation
of V/F and ka on the ability to estimate CL/F, the parameter of most interest, V/F
and ka, were fixed to more-reliable values and only CL/F was estimated in the
modeling process. Data from a traditional pharmacokinetic study consisting of
intensive sampling per individual in a given dosing interval were analyzed using
NONMEM to obtain values for V/F and ka. These values were subsequently used
to fix V/F and ka in the analysis of the population data. Thus, analysis of the
population data was performed using two models: model 1 in which all three
pharmacokinetic parameters were estimated and model 2 in which fixed esti-
mates of V/F and ka were used and only CL/F was estimated.
Briefly, the data from the traditional study consisted of 190 observations from
19 HIV-infected patients who received nelfinavir monotherapy at doses of 500 or
750 mg TID. Data were obtained from a phase II clinical trial, the results of
which have previously been reported (9). Each patient provided 10 plasma
samples at the following times: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 8 h
postdose during a steady-state dosing interval on day 28 of treatment. No patient
was taking drugs that were known inhibitors or inducers of CYP3A4.
RESULTS
The demographic characteristics of the 174 patients in the
population analysis are summarized in Table 1. The mean age
was 37 years (range, 21 to 63 years), and mean total body
weight was 78 kg (range, 42 to 140 kg). The patient population
was predominantly male (89%) and Caucasian (78%).
A one-compartment model and a two-compartment model
with first-order absorption and first-order elimination were
used to fit the data. It was not possible to obtain model con-
vergence when the two-compartment model was fit to the data;
thus a one-compartment model was used. The first-order ab-
sorption model provided a significantly better fit to the data
than the zero-order absorption model. Thus, the best basic
model consisted of the one-compartment model with first-
order absorption and first-order elimination. Interindividual
variability was best described using an exponential-error mod-
el, and intraindividual variability was best described by a com-
bined proportional- and additive-error model.
Convergence was achieved using a one-compartment model
employing model 1 (all three pharmacokinetic parameters
were estimated) and model 2 (V/F and ka were fixed to esti-
mates obtained from analysis of the traditional pharmaco-
kinetic data). The mean parameter estimates (95% CI are in
parentheses) from analysis of the traditional data were as fol-
lows: CL/F, 39.1 liters/h (30.1 to 48.1 liters/h); V/F, 229 liters
(161 to 297 liters); ka, 0.845 h
21 (0.60 to 1.13 h21). Thus, V/F
and ka were fixed to 229 liters and 0.845 h
21, respectively, in
model 2.
The basic population pharmacokinetic parameter estimates
(95% CI are in parentheses) from the fit of model 1 to the data
were as follows: CL/F, 40.7 liters/h (37.7 to 43.7 liters/h); V/F,
731 liters (531 to 931 liters); ka, 1.22 h
21 (0.70 to 1.74 h21).
The variability in the estimate of CL/F, expressed as approxi-
mate percent coefficient of variation, was 36%. When a term
for interindividual variability was included in V/F, the value
tended towards zero. Thus it was not possible to model inter-
individual variability in V/F. A large degree of interindividual
variability, 214%, was associated with ka. Model 2 provided
estimates of CL/F and its variability of 39.4 liters/h (36.3 to 42.5
liters/h) and 39%, respectively. These estimates agreed well
with the estimates obtained using model 1. In turn, estimates of
CL/F using both models agreed favorably with the estimate
that was obtained from analysis of the traditional data.
The patient covariates that significantly influenced CL/F us-
ing both models 1 and 2 are shown in Table 2. A baseline CD4
count less than 100 cells per ml and concomitant use of either
a macrolide antibiotic or fluconazole resulted in a significant
decrease in the estimate of CL/F. The magnitudes of reduction
in CL/F using either model 1 or model 2 were similar and were
17 to 19, 23 to 24, and 26 to 27% for CD4 count and macrolide
and fluconazole use, respectively. A significant increase in
CL/F of 55% was observed in patients taking rifabutin using
model 1. In contrast, a non-statistically significant increase of
37% in CL/F was observed using model 2. Due to the lack of
a consistently statistically significant effect of rifabutin and the
small number of patients in the study taking rifabutin, this
covariate was excluded from the model-building procedure.
Neither age, weight, dose level, sex, ethnic origin, baseline viral
load, M8-to-nelfinavir plasma ratio, history of liver disease, nor
LFTs grade two or higher appeared to influence CL/F in this
group of patients.
The full model consisted of a low baseline CD4 count and
concomitant use of either a macrolide antibiotic or flucon-
azole. A backward elimination process was then employed to
eliminate nonsignificant covariates from the full model to de-
velop the final model. The final model parameters using both
models are shown in Table 3. The equations for CL/F were as
follows. For model 1 (all parameters estimated), CL/F 5
42.7(1 2 0.256 z flu) liters/h where flu 5 1 if the patient was
taking concomitant fluconazole therapy. For model 2 (V/F and
TABLE 1. Characteristics of 174 patients evaluated in the
population pharmacokinetic analysis of nelfinavir
Characteristic No. ofpatients
% Total study
population
Sex (men/women) 155/19 89/11
Mean age (range) 37 (21–63)b
Mean total body weight (range) 77.7 (42–140)c
Baseline CD4 count (cells per ml)
,100 35 20
,300 and .100 59 34
,300 80 46
Baseline viral RNA (copies/ml)
.100,000 68 39
.50,000 and ,100,000 43 25
.50,000 63 36
Race
Caucasian 136 78
Black 21 12
Asian 3 2
Hispanic 7 4
Latin American 4 2
Native American 3 2
Concomitant medications
Azole (fluconazole) 25 (23) 15 (13)
Macrolide 18 10
Quinolone 12 8
Rifabutin 5 3
History of liver disease 60 34
LFTs grade 2 or higher 51 29
Plasma M8-to-nelfinavir ratioa
Low ratio (,0.1) 6 3
Intermediate ratio (.0.1 and ,0.3) 67 38
High ratio (.0.3) 37 21
a M8 concentrations were available for only 110 of 174 patients in this study.
b In years.
c In kilograms.
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ka fixed), CL/F 5 41.9(1 2 0.273 z flu) liters/h where flu was as
defined above.
The estimates of CL/F for patients not taking fluconazole
derived from the two models were comparable, 42.7 and 41.9
liters/h for models 1 and 2, respectively. Additionally, the effect
of fluconazole was similar in both models, resulting in a reduc-
tion in clearance of 26 to 27%. Interindividual variability in
CL/F was reduced marginally from 36 to 34% and from 39 to
36% using models 1 and 2, respectively. After controlling for
use of fluconazole, use of a macrolide antibiotic or a low
baseline CD4 count did not significantly affect CL/F in either
model. Thus it was not necessary to include either of these
covariates in the final models for CL/F.
This data set was also analyzed using the FOCE method in
NONMEM. The only covariate found to be of statistical sig-
nificance was concomitant use of fluconazole. In contrast to
the FO method, a low CD4 count, concomitant use of a mac-
rolide antibiotic, and concomitant use of rifabutin were either
of borderline significance or not significant at all when tested
alone in CL/F and thus were not included in the full model.
Thus, the final model included only the effect of concomitant
fluconazole. Parameter estimates for the final models are
shown in Table 3. The estimates of CL/F using FOCE were
44.9 and 45.1 liters/h for models 1 and 2, respectively. These
results compare favorably with the results obtained from the
FO method, 42.7 and 41.9 liters/h, respectively. Additionally,
the reductions in CL/F observed in patients taking concomitant
fluconazole of 26 and 30% for models 1 and 2, respectively, are
in good agreement with the reductions of 26 and 27% obtained
using the FO method.
DISCUSSION
The pharmacokinetic parameters of nelfinavir were best de-
scribed by a one-compartment open model with first-order
absorption and first-order elimination. It proved difficult to
TABLE 2. Summary of analyses of significant effects of patient covariates tested alone in CL
Hypothesis Parameterization(CL/F) Null value u4 (95% CI)
Change in objective
function P
Model 1 (do the following affect CL/F?)
CD4 , 100 cells per ml u1(1 2 u4 z cd4) 0 0.19 (0.02, 0.36) 10.014 ,0.01
Concomitant medications
Fluconazole u1(1 2 u4 z flu) 0 0.26 (0.11, 0.40) 17.225 ,0.01
Macrolide u1(1 2 u4 z mac)a 0 0.24 (0.02, 0.46) 10.784 ,0.01
Ribabutin u1(1 1 u4 z rif)b 0 0.55 (0.32, 0.77) 6.035 ,0.05
Model 2 (do the following affect CL/F?)
CD4 , 100 cells per ml u1(1 2 u4 z cd4) 0 0.17 (0.01, 0.33) 6.978 ,0.01
Concomitant medications
Fluconazole u1(1 2 u4 z flu) 0 0.27 (0.15, 0.40) 18.531 ,0.01
Macrolide u1(1 2 u4 z mac) 0 0.23 (0.06, 0.41) 10.132 ,0.01
Rifabutin u1(1 1 u4 z rif) 0 0.37 (0.17, 0.57) 3.012 Not significant
a mac, value of 1 for concomitant macrolide therapy and 0 otherwise.
b rif, value of 1 for concomitant rifabutin therapy and 0 otherwise.
TABLE 3. Final population pharmacokinetic parameters for model 1 and model 2a
Parameter
(units)e
Model 1 Model 2
Parameter estimate
(95% CI)
Interpatient variabilityb
(95% CI)
Parameter estimate
(95% CI)
Interpatient variabilityb
(95% CI)
FO method
u1
c (liters/h) 42.7 (39.3–46.1) 34 (27–39) 41.9 (38.7–45.1) 36 (28–43)
u2 (liters) 736 (501–971) NI
f 229 (fixed) 81 (65–94)
u3 (h
21) 1.19 (0.200–2.18) 142 0.845 (fixed) NI
u4
c 0.256 (0.111–0.401) NAg 0.273 (0.150–0.396) NA
s1
2 0.106 (0.028–0.184) NA 0.025 (20.015–0.064)d NA
s2
2 (mg/liter)2 0.265 (0.014–0.516) NA 0.537 (0.300–0.778) NA
FOCE method
u1
c (liters/h) 44.9 (40.9–48.9) 34 (28–40) 45.1 (41.6–48.6) 34 (27–39)
u2 (liters) 769 (363–1,175) 53 229 (fixed) 99 (76–117)
u3 (h
21) 1.34 (21.76–4.44) 58 0.845 (fixed) NI
u4
c 0.26 (0.13–0.40) 0.305 (0.181–0.429)
s1
2 0.09 (0–0.18) NA 0.04 (20.005–0.08)d NA
s2
2 (mg/liter)2 0.28 (0–0.55) NA 0.47 (0.28–0.66) NA
a Model 1, all three parameters are estimated; model 2, V and ka are fixed to 229 liters and 0.845 h21, respectively.
b Approximate coefficient of variation.
c CL/F 5 u1(1 2 u4 z flu) liters/h where flu 5 1 if the patient was taking concomitant fluconazole therapy and 0 otherwise.
d This estimate was close to zero and the 95% CI included the null value, indicating that this term was not required in the residual error model when using model 2.
e u2, V/F; u3, ka.
f NI, not identifiable.
g NA, not applicable.
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obtain accurate estimates of V/F and ka in the analysis of this
data set. In previous phase I studies, V/F has been estimated as
2 to 7 liters/kg (140 to 490 liters for a 70-kg man) (Agouron
prescribing information). The estimate from this analysis was
much larger (734 liters) and was associated with a large CI.
The estimate of ka was also associated with a large CI and a
very large degree of interindividual variability. The ability to
obtain accurate estimates of pharmacokinetic parameters de-
pends on the timing and number of plasma samples. In this
study, only one early level per dosing interval was taken in each
individual. This level was taken at essentially the same time in
every individual, 2 h after the dose. This is close to the reported
Tmax of nelfinavir (2.5 to 3 h) (9), a period of the concentra-
tion-time profile associated with inherent variability as plasma
concentrations change markedly. It is likely that this inherent
variability in observed plasma concentrations within an indi-
vidual, the lack of variability in the timing of the early postdose
levels between individuals, and the small number of early sam-
ples per individual made it difficult to obtain accurate esti-
mates of V/F and ka. Additionally, the difficulty in estimating
these parameters may be compounded by the lack of informa-
tion in the data set on factors that can influence the absorption
and/or bioavailability of nelfinavir. Studies have demonstrated
that the Cmax and area under the concentration-time curve
(AUC) of nelfinavir are two to three times higher in fed than
in fasted subjects (Agouron prescribing information; B. D.
Quart, S. K. Chapman, J. Peterkin, et al., Abstr. 2nd Natl.
Conf. Hum. Retroviruses Related Infect., abstr. 167, 1995). In
this study the quantity and type of food were not strictly con-
trolled, which may have contributed to the variability in the
rate of absorption (14). Due to the problems encountered in
estimating V/F and ka in this particular data set, the estimates
that were obtained should be interpreted with caution.
In order to assess any influence of misestimation of V/F and
ka on the estimation of CL/F, two models were used in the
analysis. In model 1, all three parameters (CL/F, V/F, and ka)
were estimated. In model 2, the values of V/F and ka were fixed
to estimates obtained from analysis of traditional pharmacoki-
netic data. The estimates obtained for CL/F and the influence
of fluconazole on CL/F were in good agreement between the
models. Thus, the estimation of CL/F and the evaluation of the
effect of covariates on CL/F in this study were not affected by
poor estimates for V/F and ka. Previously, Wade et al. investi-
gated the effect of misspecification of ka on the ability to
estimate CL using sparsely sampled simulated data (15). They
found that misspecification of ka did not markedly affect the
ability to estimate CL. The estimates obtained for CL/F were
42.7 and 42.0 liters/h using models 1 and 2, respectively. These
values compare favorably with previous estimates of the
steady-state CL/F of nelfinavir of 37.4 (17) and 46.0 liters/h
(calculated as dose/AUC from 0 to 8 h [AUC0–8]) (9).
Azole antifungal agents are commonly prescribed for pa-
tients with HIV disease for the treatment and prophylaxis of
fungal infections (4). In this study, 25 of 174 patients (15%)
were receiving concomitant azole therapy. Since 23 of these 25
patients were taking fluconazole, it was only possible to assess
the effect of this azole antifungal on the CL/F of nelfinavir.
Fluconazole is a known inhibitor of CYP3A4 and CYP2C19,
the primary isoenzymes involved in the metabolism of nelfina-
vir (Wu et al., 5th Int. ISSX Meet.; Zhang et al., 12th Int.
Symp. Microsomes Drug Oxidations). This study found that
patients receiving concomitant therapy with fluconazole expe-
rienced a statistically significant reduction in CL/F of 26 to
27% compared to patients not taking fluconazole. This effect
on the CL/F of nelfinavir is probably attributable to inhibition
of CYP2C19 since the concentrations of the principal metab-
olite, M8 (which is generated only by CYP2C19 in vitro), in
plasma are markedly decreased in the presence of fluconazole
(Zhang et al., 12th Int. Symp. Microsomes Drug Oxidations).
However, it is unlikely that an effect of this magnitude would
be clinically significant and would warrant dosage adjustment
since serious dose-limiting toxicities and concentration-related
toxicities are not apparent with nelfinavir. A controlled, pro-
spective study with intensive pharmacokinetic sampling would
allow this modest effect of fluconazole to be quantified with
improved confidence.
An effect of similar magnitude was observed in patients who
were taking ritonavir concomitant with therapy with flucon-
azole (1, 5), whereas patients treated with indinavir concom-
itant with fluconazole therapy experienced a nonsignificant
increase in CL/F (3). The inconsistency of fluconazole’s inhib-
itory effect towards the various protease inhibitors in vivo may
be accounted for by different contributions of cytochrome P450
isoenzymes (CYP3A4 versus non-CYP3A4) to the metabolism
of these drugs and differing sensitivities of the various P450
isoenzymes to fluconazole.
Concomitant use of a macrolide antibiotic and a baseline
CD4 count less than 100 cells per ml were statistically signifi-
cant covariates for CL/F when tested alone (Table 2). How-
ever, the influence of concomitant fluconazole therapy was
greater, and once this effect had been incorporated into the
final model for CL/F, the effects of concomitant use of a mac-
rolide antibiotic and a low baseline CD4 count were no longer
statistically significant. It should be noted that 16 of the 35
patients with a low CD4 count were taking fluconazole and 8 of
the 18 patients receiving concomitant macrolide therapy were
also taking fluconazole. Thus, the observed influence of a low
CD4 count and concomitant macrolide therapy may be ex-
plained by the high percentage of patients with these charac-
teristics who were also taking fluconazole.
In this study, the CYP2C19-metabolizing status of the pa-
tient was evaluated indirectly as a covariate in CL/F by means
of the M8-to-nelfinavir plasma ratio. The M8 metabolite is
predominantly formed by the cytochrome P450 isoenzyme,
CYP2C19 (Lillibridge et al., 5th Int. ISSX Meet.; Wu et al., 5th
Int. ISSX Meet.). Previous studies (Lillibridge et al., 5th Int.
ISSX Meet.; Zhang et al., 12th Int. Symp. Microsomes Drug
Oxidations) indicate that the plasma M8-to-nelfinavir ratio is
substantially reduced and plasma nelfinavir concentrations are
modestly increased when CYP2C19 enzyme activity is im-
paired (genotypic poor metabolizers and/or concomitant drugs
that inhibit CYP2C19). In this study, the plasma M8-to-nelfi-
navir ratio was not found to be a significant covariate for CL/F
of nelfinavir. However, five of the six patients in this study with
a low plasma M8-to-nelfinavir ratio (ratio, ,0.1) were also
receiving fluconazole. Thus, the lack of significance for the
plasma M8-to-nelfinavir ratio as a covariate may be explained
in part by a correlation with concomitant use of fluconazole
(itself a significant covariate).
The effect of rifabutin on the CL/F of nelfinavir was incon-
sistent using the models in this analysis. It is probable that this
study did not have sufficient power to assess the influence of
rifabutin on the CL/F of nelfinavir, since only 5 of the 174
patients in the study were taking rifabutin. In both models,
there was a trend for concomitant rifabutin to increase the
CL/F of nelfinavir (from 37 to 55%). However, only when all
three pharmacokinetic parameters (ka, V/F, and CL/F) were
estimated did the increase achieve statistical significance.
There is evidence from other clinical studies that rifabutin
induces the metabolism of nelfinavir when given TID (Ag-
ouron prescribing information). It is likely that a larger number
of patients taking concomitant therapy with rifabutin in this
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study population would have confirmed the existence of a
significant effect on CL/F.
The FO method in NONMEM involves linear assumptions,
whereas the FOCE method does not. These assumptions in-
crease the risk of obtaining biased parameter estimates. How-
ever, the FOCE method is computationally more complex than
the FO method, resulting in a substantially longer time to run
an analysis. A limited comparison of some linear approxima-
tion methods (e.g., the FO method) with computationally more
intensive approximation methods (e.g., the FOCE method) has
shown that the linear approximation methods perform ade-
quately (12). In this study, the population pharmacokinetic
parameters were obtained initially by implementing the FO
method in NONMEM and the results were confirmed using
the FOCE method. The final models using both methods did
compare favorably, showing that, in this instance, the FO
method provided adequate estimates that were similar to the
estimates obtained with the FOCE method.
In conclusion, the population pharmacokinetic parameters
of nelfinavir were best described using a one-compartment
model with first-order absorption. Estimation of V/F and ka
was difficult using this data, and the values obtained should be
interpreted with caution. The estimate of CL/F was approxi-
mately 42.7 liters/h. There appeared to be no effect of body
weight, age, sex, or ethnicity on the CL/F of nelfinavir in this
study. Patients receiving concomitant therapy with fluconazole
had a modest reduction in CL/F of 26 to 27%. This finding
appears to be of little clinical significance given the safety of
nelfinavir, and no dosage adjustment is indicated.
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